How India Exports Enoxaparin to the World

In the United States, enoxaparin is regulated by the Food and Drug Administration (FDA) and is available as both branded and generic formulations. The approval of generic enoxaparin under the Abbreviated New Drug Application (ANDA) pathway necessitates demonstrating equivalence to the reference product in terms of physicochemical properties, heparin source material, disaccharide composition, biological activity, and in vivo pharmacodynamic profile. This rigorous framework ensures the safety and efficacy of generic enoxaparin products.

Given that the United States is the leading importer of Indian enoxaparin exports, accounting for 49.0% of the total export value, Indian manufacturers must adhere to FDA regulations to access this market. The presence of 223 active Indian exporters underscores the competitive landscape and the importance of maintaining compliance with FDA standards to ensure market entry and sustainability.

In the European Union (EU), enoxaparin is subject to the European Medicines Agency's (EMA) regulatory oversight. Products like Inhixa, a biosimilar enoxaparin, have received marketing authorization, indicating compliance with EU standards. However, the marketing authorization for Thorinane, another enoxaparin product, lapsed on 15 September 2019 due to the product not being marketed within three years of authorization, as per the EU's "sunset clause." (ema.europa.eu)

The United Kingdom, post-Brexit, has established its own regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA). For instance, in June 2025, the MHRA issued a Class 2 medicines recall for Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection due to a typographical error on the packaging. (gov.uk)

Enoxaparin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in healthcare systems worldwide. The WHO Prequalification Programme ensures that medicines like enoxaparin meet global standards of quality, safety, and efficacy, facilitating their procurement by international agencies.

Pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) provide detailed monographs for enoxaparin, ensuring consistency and quality across different markets.

In India, enoxaparin is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including enoxaparin, to ensure affordability. Manufacturers intending to export enoxaparin must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

The primary patents for enoxaparin have expired, leading to increased generic competition globally. This has resulted in a more competitive market landscape, with multiple manufacturers producing generic versions of enoxaparin, thereby enhancing accessibility and affordability.

In June 2025, the MHRA issued a Class 2 medicines recall for Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection due to a typographical error on the packaging, highlighting the importance of accurate labeling in pharmaceutical products. (gov.uk)

In March 2026, the EMA updated the European Public Assessment Report (EPAR) for Inhixa, reflecting ongoing regulatory oversight and the importance of maintaining up-to-date product information. (ema.europa.eu)

These developments underscore the dynamic nature of the regulatory environment for enoxaparin and the necessity for manufacturers to stay informed and compliant with evolving standards to ensure market access and patient safety.

The production of Enoxaparin relies heavily on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India's pharmaceutical industry is notably dependent on China for these critical components. According to a report by the U.S.-China Economic and Security Review Commission published in November 2025, India's production of dexamethasone, used to treat inflammatory and autoimmune conditions, relies on key chemicals such as diosgenin, which is no longer available in India and has to be imported, presumably from China. This dependency exposes the Enoxaparin supply chain to potential disruptions stemming from geopolitical tensions, trade disputes, or regulatory changes in China.

Recent disruptions have underscored this vulnerability. In June 2021, manufacturing issues led to a disruption in the supply of Enoxaparin (Clexane®) 20 mg and 40 mg syringes, as reported by the New South Wales Health Department. Such incidents highlight the fragility of the supply chain and the need for diversification in sourcing strategies.

The Enoxaparin export market from India is highly concentrated, with the top five exporters accounting for 86.8% of total exports. GLAND PHARMA LIMITED alone contributes $79.0 million USD, representing a 37.7% share. This high level of supplier concentration poses a significant risk; any operational, financial, or compliance issues within these key suppliers could lead to substantial supply disruptions.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base and enhancing supply chain resilience remains to be fully realized.

Global geopolitical tensions and shipping disruptions further threaten the Enoxaparin supply chain. The Red Sea and the Strait of Hormuz are critical maritime routes for global trade; any instability in these regions can lead to delays and increased shipping costs. Additionally, escalating tensions between the United States and China have resulted in trade restrictions and tariffs, potentially affecting the availability and cost of KSMs and APIs sourced from China.

These factors have contributed to intermittent shortages of Enoxaparin. For instance, in February 2026, Medfinder reported ongoing disruptions in the supply of Enoxaparin Sodium (Lovenox) in the United States, with certain syringe strengths being disproportionately affected. Such shortages can have significant clinical implications, necessitating the use of alternative therapies and posing challenges for healthcare providers.

To enhance the resilience of the Enoxaparin supply chain, the following actions are recommended:

• Diversify API and KSM Sources: Encourage the development of alternative sources for APIs and KSMs, both domestically and from other countries, to reduce dependency on a single nation.

• Strengthen Domestic Manufacturing: Invest in domestic production capabilities for critical raw materials and intermediates to mitigate risks associated with import reliance.

• Expand Supplier Base: Promote the growth of small and medium-sized enterprises (SMEs) in the pharmaceutical sector to reduce supplier concentration and enhance competition.

• Enhance Supply Chain Transparency: Implement robust tracking and monitoring systems to identify potential disruptions early and facilitate proactive responses.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including maintaining strategic reserves and identifying alternative logistics routes, to address potential geopolitical and shipping disruptions.

RISK_LEVEL: HIGH